[1] Law, M.R., Wald, N.J. and Rudnicka, A.R. (2003) Quantifying Effect of Statins on Low Density Lipoprotein Cholesterol, Ischaemic Heart Disease, and Stroke: Systemic Review and Meta-Analysis. BMJ, 326, 1423.
https://doi.org/10.1136/bmj.326.7404.1423
[2] Zodda, D., Giammona, R. and Schifilliti, S. (2018). Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharmacy (Basel, Switzerland), 6, 10.
https://doi.org/10.3390/pharmacy6010010
[3] Davidson, M., Ma, P., Stein, E.A., Gotto, A.M., Raza, A., Chitra, R. and Hutchinson, H. (2002) Comparison of Effects on Low-Density Lipoprotein Cholesterol and High-Density Lipoprotein Cholesterol with Rosuvastatin versus Atorvastatin in Patients with Type IIa or IIb Hypercholesterolemia. American Journal of Cardiology, 89, 268-275.
https://doi.org/10.1016/S0002-9149(01)02226-3
[4] Paoletti, R., Fahmy, M., Mahla, G., Mizan, J. and Southworth, H. (2001) Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study. Cardiovascular Risk, 8, 383-390.
https://doi.org/10.1177/174182670100800608
[5] Adams, S.P., Sekhon, S.S. and Wright, J.M. (2014) Lipid-Lowering Efficacy of Rosuvastatin. Cochrane Database of Systematic Reviews, No. 11, CD010254.
[6] Canadian Agency for Drugs and Technologies in Health (2015) Similarities and Differences between Brand Name and Generic Drugs.
https://www.cadth.ca/sites/default/files/pdf/simi
larities_differences_brandname_generic_drugs_e.pdf
[7] Gallelli, L., Palleria, C., De Vuono, A., Mumoli, L., Vasapollo, P., Piro, B. and Russo, E. (2013) Safety and Efficacy of Generic Drugs with Respect to Brand Formulation. Journal of Pharmacology & Pharmacotherapeutics, 4, 110-114.
https://doi.org/10.4103/0976-500X.120972
[8] Iosifescu, A., Halm, E.A., McGinn, T., Siu, A.L. and Federman, A.D. (2008) Beliefs about Generic Drugs among Elderly Adults in Hospital-Based Primary Care Practices. Patient Education and Counseling, 73, 377-383.
https://doi.org/10.1016/j.pec.2008.07.012
[9] Lopez, V.A., Franklin, S.S., Tang, S. and Wong, N.D. (2007) Coronary Heart Disease Events Preventable by Control of Blood Pressure and Lipids in US Adults with Hypertension. The Journal of Clinical Hypertension (Greenwich), 9, 436-443.
https://doi.org/10.1111/j.1524-6175.2007.06518.x
[10] Bart, B.Y., Luchinkina, E.E., Gordeev, I.G., Arutyunov, G.P. and Taratukhin, E.O. (2016) On Behalf of the Workgroup of Paritet Trial. Comparative Analysis of the Efficacy and Safety of Rosuvastatin and Original Rosuvastatin. Kardiologiia, 56, 46-49.
https://doi.org/10.18565/cardio.2016.6.46-49
[11] Abd-Elaziz, K.M., Gabal, M.S., Aldafrawy, O.A., Abou-Seif, H.A.-A. and Allam, M.F. (2014) Prevalence of Metabolic Syndrome and Cardiovascular Risk Factors among Voluntary Screened Middle-Aged and Elderly Egyptians. Journal of Public Health, 37, 612-617.
https://doi.org/10.1093/pubmed/fdu097
[12] Abd-Allah, F., Khedr, E., Oraby, M.I., Bedair, A.S., Georgy, S.S. and Moustafa, R.R. (2017) Stroke Burden in Egypt: Data from Five Epidemiological Studies. International Journal of Neuroscience, 1-7.
[13] Almahmeed, W., Arnaout, M.S., Chettaoui, R., Ibrahim, M., Kurdi, M.I., Taher, M.W. and Mancia, G. (2012) Coronary Artery Disease in Africa and the Middle East. Therapeutics and Clinical Risk Management, 8, 65-72.
https://doi.org/10.2147/TCRM.S26414
[14] Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A.H., Mauskopf, J. and Loder, E. (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health, 16, 231-250.
https://doi.org/10.1016/j.jval.2013.02.002
[15] Rascati, K.L. (2014) Essentials of Pharmacoeconomics. 2nd Edition, Lippincott Williams & Wilkins, Philadelphia.
[16] Arenas-Guzman, R., Tosti, A., Hay, R. and Haneke, E. (2005) National Institute for Clinical Excellence. Pharmacoeconomics: An Aid to Better Decision-Making. The Journal of the European Academy of Dermatology and Venereology, 19, 34-39.
https://doi.org/10.1111/j.1468-3083.2005.01285.x
[17] Ambrosioni, E. and Borghi, C. (2014) Pharmacoeconomic and Cost-Benefit Aspects. In: Manual of Hypertension of the European Society of Hypertension, CRC Press, Boca Raton, 316-320.
https://doi.org/10.1201/b17072-51